Urelumab - Bristol-Myers Squibb

Drug Profile

Urelumab - Bristol-Myers Squibb

Alternative Names: Anti-4-1BB monoclonal antibody; Anti-CD137 monoclonal antibody - Medarex/Bristol-Myers Squibb; BMS-663513; BMS-66513; ONO-4481

Latest Information Update: 08 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Medarex
  • Developer Bristol-Myers Squibb; National Cancer Institute (USA); Ono Pharmaceutical; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • Class Antineoplastics; Disulfides; Immunoglobulins; Monoclonal antibodies
  • Mechanism of Action CD137 antigen agonists; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-Hodgkin's lymphoma; Solid tumours
  • Phase I Glioblastoma; Multiple myeloma
  • No development reported Colorectal cancer; Head and neck cancer; Malignant melanoma
  • Discontinued Non-small cell lung cancer

Most Recent Events

  • 08 Nov 2017 Urelumab is still in phase I trials for Multiple Myeloma in USA and Spain (NCT02252263)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Colorectal-cancer(Combination therapy, Late-stage disease, Metastatic disease) in USA (IV, Infusion)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Head-and-neck-cancer(Combination therapy, Late-stage disease, Metastatic disease) in USA (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top